Abstract
A Genomic Signature Predicting Venetoclax Treatment Response in Acute Myeloid Leukemia (AML) Identified By Protein Network Mapping and Validated By Ex Vivo Ddrug Sensitivity Testing
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have